This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Randomized Controlled Trial  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2005;293:1312-1315.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Unpublished findings from a recently halted hypertension treatment trial has left some experts calling for changes to current guidelines for the control of high blood pressure and others preaching caution about making such changes until a detailed analysis of the new data is completed.

The source of the dispute is data from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), which was halted in December at the recommendation of the trial’s independent data safety monitoring board when an interim analysis of the data found that a newer treatment strategy of amlodipine (a calcium channel blocker) and perindopril (an angiotensin-converting enzyme inhibitor) was superior to the older treatment regimen of atenolol (a -blocker) and bendroflumethiazide (a thiazide diuretic).

Experts are divided over whether findings from the ASCOT trial warrant changes in treatment guidelines for high blood pressure. (Photo credit: ASCOT)

The trial, which involved 19 000 European patients with hypertension, began in . . . [Full Text of this Article]

DUELING DATA?



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?